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Background:  Triclosan  (TCS)  is an  antibacterial  agent  commonly  added  to personal  care  products.  Some
animal  research  studies  have  associated  TCS  exposure  with  androgenic  and  thyroid  effects,  as  well  as
endocrine  disruption,  contact  dermatitis  and  skin  irritation.  Limited  Canadian  data  exist  on exposure
levels,  temporal  variability  and  sources  of exposure  to TCS,  especially  among  pregnant  women.
Methods:  Single  and  serial  spot  urine  samples  (n = 1249),  as  well  as  consumer  product  use information
were  collected  over  5 study  visits  across  pregnancy  and  post-partum  from  80  healthy  pregnant  women
in  Ottawa,  Canada.  Urine  samples  were  analyzed  for TCS  by GC–MS–MS.  Summary  statistics,  linear  mixed
effects  models,  and  surrogate  category  analysis  were  used  to describe  the  results.
Results:  Triclosan  was  detected  in 87%  of  maternal  urine  samples  (LOD  =  3.0  g/L).  The  geometric  mean
TCS concentration  of  all  urine  samples  was 21.6  g/L  (95%  CI  18.2–25.7).  Triclosan  concentrations  were
signiﬁcantly  higher  when  the  urine  was  collected  before  16:00,  in the  autumn,  and  more  than  90  min
since  last  void,  and in  nulliparous  women  with  household  incomes  greater  than  $100,000.  A signiﬁcant
correlation  was  observed  between  maternal  urinary  TCS  concentrations  and  number  of reported  uses  of
TCS-containing  products.  The  ability  of  a single  spot  urine  sample  collected  at any  time  during  or  post-
pregnancy  to predict  an  individual’s  geometric  mean  urinary  TCS  level  corresponding  to  low,  medium,
or  high  exposure  was  86.7%.  Intraclass  correlation  coefﬁcients  indicated  high  reproducibility  within  a
week-day  (0.77)  and  week-end  day  (0.79)  and  moderate  reproducibility  across  the  study  period  (0.50).
Conclusions:  This  study  provided  the  ﬁrst data  on temporal  variability  of  urinary  TCS concentrations  and
predictors  of exposure  in Canadian  pregnant  women.  These  results  can  inform  exposure  assessments  in
pregnant  women  and  justify  collection  of  single  spot  urine  samples  in  epidemiologic  studies,  especially
for  women  with higher  exposures.
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Triclosan (TCS) is an antimicrobial agent commonly added
o personal-care products including toothpastes, mouthwashes,
oaps, deodorants, and cosmetics (Government of Canada, 2013). It
s also used in drug products and natural health products, including
oot gels, acne treatments, body sprays, skin cleansers, and lotions
Government of Canada, 2012b). Until 2011, the number of TCS-
ontaining consumer products had been increasing (Alliance for the
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c-nd/4.0/).5  Published  by Elsevier  GmbH.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Prudent Use of Antibiotics, 2011). However, there has been a steady
decline in the number of TCS products in the last few years, with
more companies eliminating or planning to eliminate it in products
in the near future (e.g. Johnson & Johnson Consumer Companies,
2015; Proctor and Gamble, 2014; Avon Products Inc., 2014). Tri-
closan is ubiquitous in the environment, is primarily excreted in
urine, does not bioaccumulate in humans, and has a short half-life
of less than 24 h in urine or faeces (SCCP, 2009; Sandborgh-Englund
et al., 2006).
Nearly all of the research on potential health effects of TCS uses
animal models; however, the results from these models are not
always applicable to humans (FDA, 2010). Although results have
been inconsistent, some animal research studies have identiﬁed
androgenic and thyroid effects due to TCS exposure (Veldhoen
et al., 2006; Kumar et al., 2009; James et al., 2010; Gee et al.,
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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children). The product booklet collected information not only on
personal care products, but also on cleaning agents, dishwashing
soaps, drugs and vitamins. It is important to note that the term08 L. Weiss et al. / International Journal of Hygie
008), as well as endocrine disruption (Allmyr et al., 2009; Kim
t al., 2011), contact dermatitis (Robertshaw and Leppard, 2007),
hoto-allergic contact dermatitis (PACD) (Schena et al., 2008) and
kin irritation (Robertshaw and Leppard, 2007) as potential effects.
 recent review of the animal and epidemiologic literature has
owever concluded that overall there is little evidence that TCS
xposure through use of personal care products presents a risk of
ndocrine disrupting activity in humans (Government of Canada,
012a; Witorsch, 2014).
Data on Canadian urinary TCS concentrations, as well as the
ources of exposure and temporal variability of TCS are limited. As
ost surveys rely on a single urine sample to estimate exposure, it
s also important to assess the reliability of a single spot urine sam-
le to estimate an individual’s exposure over the longer term. It is
specially important to study pregnant women, as the developing
oetus has an increased risk of experiencing adverse effects from
ndocrine modulation (Woodruff et al., 2008). To date, information
n TCS source attribution among pregnant women is limited with
ne study reporting a positive association between TCS concentra-
ions and the use of certain personal care products (Meeker et al.,
013).
Triclosan concentrations have been measured in the general
opulation (Calafat et al., 2008; Clayton et al., 2011; Teitelbaum
t al., 2008; Kim et al., 2011; Li et al., 2013; Health Canada, 2013;
assen et al., 2013), small subsets of the Canadian general pop-
lation (Environmental Defence, 2012) as well as in pregnant
opulations (Bertelsen et al., 2014; Casas et al., 2011; Meeker et al.,
013; Philippat et al., 2012; Wolff et al., 2008; Woodruff et al., 2011;
hilippat et al., 2013; Arbuckle et al., 2015a).
Signiﬁcant costs and participant burden arise when collecting
nd analyzing serial urine samples. To date, several studies have
easured the temporal variability in exposure to TCS (Teitelbaum
t al., 2008; Meeker et al., 2013; Lassen et al., 2013; Philippat et al.,
013; Bertelsen et al., 2014) in various populations, including men,
hildren, and pregnant women. However, none of the previous
tudies of pregnant women have measured temporal variability
ithin a day as well as across pregnancy and into the post-partum
eriod.
This study was designed to provide Canadian biomonitoring
ata and information on intra-individual variability within a day
nd across pregnancy and identify potential sources of TCS expo-
ure. Given the susceptibility of pregnant women (and their foetus)
o environmental chemicals, it is important that this population be
tudied.
ethods
tudy design
The Plastics and Personal-Care Product use in Pregnancy (P4)
tudy is a longitudinal observational study examining exposure of
regnant women to non-persistent chemicals, including TCS, across
regnancy as well as into the post-partum period. The P4 Study
eceived ethical approval from Health Canada and the ethics com-
ittees at each of the local hospitals. Each study participant signed
n informed consent form.
tudy population
Eighty pregnant women were recruited for the study from
osters in physician ofﬁces, contacts with midwives, and from
bstetrical clinics in Ottawa, Canada between November 2009
nd December 2010. Eligibility criteria stipulated that participants
e 18 years or older, with the ability to consent and communi-
ate in English or French, less than 20 weeks gestation, with a Environmental Health 218 (2015) 507–513
singleton, viable foetus, planning on delivering at a local hospital
or at home. Women  with known foetal abnormalities (e.g. hyda-
tidiform mole), known foetal chromosomal anomalies or major
malformations in their current pregnancy were excluded from the
study. Also excluded were women  with a history of any medical
complications (e.g. renal disease, thyroid disorder, hypertension,
and diabetes), threatened spontaneous abortion, or illicit drug use.
However, participants were allowed to continue in the study if
any of these health conditions developed or were identiﬁed after
recruitment.
Maternal urine collection
Urine samples were collected at ﬁve different study visits
throughout pregnancy as well as post-partum. The sampling sched-
ule is shown in Table 1. At visit T1 (less than 20 weeks gestation),
women were instructed to collect all their urine samples as serial
spot urine voids over a 24-h period during both a week-day (T1a)
and/or a week-end day (T1b). Visits T2 (2nd trimester, 24–28
weeks), T3 (3rd trimester, 32–36 weeks) and T5 (2–3 months
post-partum) consisted of single spot urine samples.1 Voids were
collected in 120 mL Nalgene® specimen cups and the time and date
of each sample was recorded. Samples were collected either in a
clinic or a research assistant collected the urine samples from the
participants’ homes and delivered them to the hospital laboratory
for processing. Urine was  kept cool (4 ◦C) at all times with the use
of ice packs, was mixed well and aliquoted within 36 h of collection
and then stored frozen at −80 ◦C in order to preserve the chemical
of interest (Ye et al., 2007).
Data collected
Questionnaires were administered to participants to collect
maternal factors (age, education, household income, country of
birth, marital status, pre-pregnancy body mass index, parity, sea-
son of collection) and information on the urine collection (volume,
time of day, season of collection, time since last void) that may
be associated with maternal triclosan concentration. Participants
completed “Product Use Booklets” and “Food and Activity Diaries”
for the 24-h period preceding visit T1a and T1b as well as during
the 24-h collection period, and for the 24-h period prior to each
single void at visits T2, T3, and T5.
Important information collected from these booklets included
the product brand name, product manufacturer, and time and day
of product use. Activities relating to the use of products were of
primary concern for this study. Speciﬁc food choices were not
expected to be highly associated with triclosan exposure; however,
participants were asked to record the type of packaging (if known)
of any prepackaged food items handled or consumed throughout
the day. In the “Food and Activity Diaries”, participants were
asked to record the details and time of activities (e.g. brushing
teeth, make-up application, house cleaning) throughout the day.
The “Product Use Booklet” contained the details of the recorded
activities (e.g. brushed teeth at 10:00am with toothpaste brand x).
This booklet included the names of speciﬁc products and brands
used throughout the day and the corresponding time of use. In
addition to products applied to her, the woman  was asked to
record any products applied to others (e.g. application of lotions to1 Study visit T4 took place at the time of delivery. No maternal urine was collected
at  this visit; however, infant urine and meconium samples were collected to address
other P4 Study research questions.
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Table  1
Maternal urine and data collection schedule.
Sample collection Early pregnancy (6–19 wks) 2nd trimester
(24–28 wks)
3rd trimester
(32–36 wks)
2–3 months
post-partum
T1a T1b T2 T3 T5
Day of the week Week-day Week-end Either Either Either
Type  of sample Multiple spot urine
samples throughout a
24 h period
Multiple spot urine
samples throughout a
24 h period
One spot urine
sample
One spot urine
sample
One spot urine
sample
Diary  and 48 h (24 h prior to 48 h (24 h prior to
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(Questionnaires sample collection
period and 24 h of
collection period)
sample collect
period and 24
collection peri
ctivities in the “Food and Activities Diary” did not include a
chedule of all daily activities. It only included details within the
aily activities that involved the use of the product (e.g. hand
oap, hand sanitizer). Numerous sources were accessed, including
he Health Canada Licensed Natural Health Products Database
http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-
rod/lnhpd-bdpsnh-eng.php) among others, in order to develop
atabases of products that contained triclosan. Each product use
ecorded in the “Product Use Booklet” was coded as either one that
ontained triclosan, did not contain triclosan or was  unsure if the
roduct contained triclosan or not due to insufﬁcient information.
aboratory analysis
The Centre de Toxicologie du Québec, Institut national de
anté publique du Québec (http://www.inspq.qc.ca/ctqenglish/)
onducted all biospecimen analyses. Triclosan was quantiﬁed in
rine samples by GC-MS–MS (gas chromatography coupled to tan-
em mass spectrometry), following a solvent extraction protocol
Arbuckle et al., 2015b). The limit of detection (LOD) was 3.0 g/L.
ll machine readings for results below the LOD were available. Spe-
iﬁc gravity of the urine was measured by refractometry (Atago
G-, Cat. # 3464) with automatic temperature compensation
ATAGO Bellevue, WA).
tatistical analysis
Data analysis was performed using Statistical Analysis Software
SAS) 9.3 (SAS Institute, Cary, NC).
A Mann–Whitney test was conducted to test for differences in
eek-day and week-end day urinary TCS concentrations, while a
ruskal–Wallis test was conducted to test for differences in TCS
oncentrations across pregnancy.
Linear mixed effects models with a random subject effect were
tted using the MIXED procedure in SAS in order to account
or potential correlations of repeated measurements within an
ndividual. Urinary TCS concentrations were not normally dis-
ributed; consequently, the concentrations were log-transformed
nd included as such in these statistical models. For the logarithmic
ransformations, a constant of 0.0001 was added to any urinary TCS
oncentrations of 0 g/L.
Speciﬁc gravity (SG) was included as a covariate in the
odel. For descriptive analysis, urinary concentrations were
djusted for speciﬁc gravity, using the following formula: Pc = Pi
(SGm − 1)/(SGi − 1)], where Pc is the SG-adjusted metabolite con-
entration (ng/ml), Pi is the observed metabolite concentration, SGi
s the speciﬁc gravity of the urine sample, and SGm is the median SG
or the cohort. Covariates included in the ﬁtted model were: study
isit (T1a, T1b, T2, T3, T5), total volume (continuous), marital sta-
us (married vs. not), education (less than college diploma, college
iploma, university degree, graduate degree), household income
≤$60,000, $60,001–80,000, $80,001–100,000, >$100,000), countrysample
collection
sample
collection
sample
collection
of birth (Canada vs. other), time of day of urine void (before 09:00,
09:00–15:59, 16:00–23:59), age (<30, 30–34, 35–39, ≥40), season
of conception, season of sampling, parity (0, 1, ≥2), and time since
last urine void (continuous). The temporal variability of TCS within
a 24-h period and throughout pregnancy was  assessed using the
intraclass correlation coefﬁcient (ICC), a measure of reproducibility,
calculated by dividing the between-subject variability by the sum of
the between- and within-subject variability, where 0 indicates no
within person reproducibility and 1 indicates perfect reproducibil-
ity. Given the large number of within-a-day samples collected in
the T1A and T1B visits, a single urine sample from each participant
for each of the 24-h periods was randomly selected for the analysis
across pregnancy. An ICC above 0.75 was  deﬁned as high; 0.40–0.75
as moderate; below 0.40 as poor reproducibility (Rosner, 2006).
Surrogate categorical analysis was  used to examine the predic-
tive ability of the single spot samples taking through pregnancy
versus a 24 h urine collection sample, through the following steps
(adapted from Braun et al., 2012): (1) the geometric mean value of
SG-adjusted TCS concentrations across all study visit samples pro-
vided was calculated for each participant; (2) this value was used
to classify participants into terciles of overall TCS exposure: low,
medium and high, corresponding to the “observed true value” for
that participant; (3) the values of each individual SG-adjusted urine
sample were also classiﬁed into the same terciles (low, medium
and high) deﬁned in step (2); these corresponded to the “predicted
value” for each individual sample; (4) contingency tables were
created to assess the agreement between single spot urine classiﬁ-
cations and an individual’s overall exposure throughout pregnancy
(as reﬂected by their SG-adjusted geometric mean). Chi-square
tests of independence were performed to test whether a signiﬁcant
difference existed between the concentrations of overall predicted
and true classiﬁcations. Speciﬁcally, the agreement of the single
spot urine samples was assessed between study visits as well as
between different times of day.
Results
The percentage of women  who  volunteered to participate in the
study was 11% of those eligible. The majority of the study popula-
tion were married (79%), born in Canada (79%) and had a household
income of greater than $100,000 (55%) (Table 2). Approximately
45% had an undergraduate university degree. The average maternal
age of the study population was  32.8 years.
There were a total of 6031 recorded products used across preg-
nancy; hand soaps/sanitizers (15.0%) and lotions/creams (14.5%)
were most frequently used by the study participants. Of the total
product uses, 266 (4.41%) were conﬁrmed to contain TCS and
4274 (70.9%) were conﬁrmed to be TCS-free. It was  not possi-
ble to determine whether or not the product contained TCS for
1491 products (24.7%) due to insufﬁcient information provided by
participants. Those products containing TCS were primarily oral
care products (46.6%) and hand soaps/sanitizers (42.4%) (Fig. 1).
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Table 2
Demographic covariates of P4 Study participants (n = 80).
Frequency Percentage
Maternal age
<30 17 21
30–34 36 45
35–39 19 24
≥40 7 9
Missing 1 1
Education
<College diploma 9 11
College diploma 14 18
Undergraduate university degree 36 45
Masters or PhD 21 26
Marital status
Married 63 79
Other 17 21
Household income
<60,001 7 9
60,001–80,000 11 14
80,001–100,000 13 16
>100,000 44 55
Missing 5 6
Country of birth
Canada 63 79
Other 17 21
Parity
0  37 46
1  34 43
≥2  9 11
Season of conception
Spring 20 25
Summer 23 29
T
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c
a
t
Table 3
Intraclass correlation coefﬁcients (ICC) of triclosan in maternal urine samples.
Time period Unadjusted Speciﬁc-gravity adjusted
T1A (week-day) 0.78 0.77
T1B (week-end) 0.79 0.79
Across all time points 0.50 0.50
Table 4
Type 3 tests of maternal and urinary collection covariates in the linear mixed effects
model predicting TCS concentrations across all study visits. Akaike Information Cri-
terion (AICC) = 2899.7. *p-Value signiﬁcant at <0.05.
Degrees of freedom F value Pr > F
Speciﬁc-gravity 1 95.34 <0.0001*
Visit 4 1.33 0.26
Total volume 1 0.44 0.51
Marital status 1 2.63 0.11
Education 3 2.81 0.05
Household Income 3 3.13 0.03*
Country of birth 1 0.03 0.85
Time of day 2 7.09 0.001*
Maternal age 3 0.53 0.66
Season of conception 3 2.21 0.10
autumn and more than 90 min  since last void were higher than
those collected at other times. Women  with household incomes
between $80,000 and 100,000 had signiﬁcantly lower TCS exposure
than women with incomes greater than $100,000. Women  with noAutumn 11 14
Winter 26 32
he number of products used per participant did not vary across
regnancy (F = 1.42, p = 0.27) (data not shown). There was a statis-
ically signiﬁcant positive correlation between the total number of
CS product uses per participant and their individual SG-adjusted
eometric mean urinary TCS level (r = 0.53, p = 0.0009) (data not
hown). Although this correlation reﬂects a combination of all prod-
cts containing TCS, it is important to note that the dose from
ifferent sources are likely not equivalent.
A total of 1247 urine samples were provided among study
articipants and 86.8% of these samples had detectable concentra-
ions of TCS. The unadjusted and SG-adjusted geometric mean TCS
oncentrations of all the maternal urine samples were 21.6 g/L
95% CI 18.2–25.7) and 22.9 g/L (19.2–27.2), respectively (data
ig. 1. Percentage of products containing TCS, by product category. Product
ategories include: cosmetics, hair care, oral care, baby products, deodor-
nt/antiperspirant, hand soaps/sanitizers, lotions/creams, skin care, medica-
ion/vitamins, household cleaning products, other products.Season of sampling 3 3.96 0.01*
Parity 2 3.69 0.03*
Time since last void 1 4.48 0.03*
not shown). An intraclass correlation coefﬁcient of 0.50 indicated
moderate reproducibility among all urine samples collected across
pregnancy; reproducibility was high among serial urine sam-
ples collected on a week-day (0.77) and a week-end day (0.79)
(Table 3). SG-adjusted geometric mean TCS concentrations did not
differ between week-day and week-end day samples (2 = 0.0026,
p = 0.96) (Fig. 2), nor between samples collected at different study
visits (Supplemental Tables 1a–e; Table 4).
The linear mixed effects model identiﬁed speciﬁc gravity, mater-
nal income, parity, and when the urine was  collected (time of day,
season, and time since last void) as signiﬁcant predictors of uri-
nary maternal TCS concentrations (Table 4). Speciﬁcally, TCS in
urine samples collected between 16:00 and 23:59 was signiﬁcantly
lower than those provided at other times and samples collected inFig. 2. Boxplot of the speciﬁc gravity adjusted geometric means (g/L) of all indi-
vidual maternal urine samples by week-day collection (1A) and week-end day
collection (1B). Y-axis log log base 10 scale.
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Table  5a
Prediction accuracy of a week-day single spot sample to correctly identify an indi-
vidual’s overall geometric mean TCS level.
Low tercile Medium tercile High tercile Total
Correct prediction 159 142 156 457
Total 166 167 173 506
Percentage 95.8% 85.0% 90.2% 90.3%
Table 5b
Prediction accuracy of a week-end day single spot sample to correctly identify an
individual’s overall geometric mean TCS level.
Low tercile Medium tercile High tercile Total
Correct prediction 145 144 136 425
Total 169 193 149 511
Percentage 85.8% 74.6% 91.3% 83.2%
Table 5c
Prediction accuracy of high urinary TCS concentrations by time of day of urine
sample collection.
00:00–08:59 09:00–15:59 16:00–23:59 Total
Correct prediction 59 135 98 292
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tive association between household income and urinary TCS levelsTotal 67 138 117 322
Percentage 88.1% 97.8% 83.8% 90.7%
revious pregnancies had urinary TCS concentrations greater than
hose with 2 or more previous pregnancies. Urinary concentrations
id not differ during or post-pregnancy.
When using a single spot urine sample to predict an individual’s
verall geometric mean urinary TCS concentration corresponding
o low, medium, or high exposure, the overall accuracy was  86.7%,
ncluding the urine samples with non-detectable levels of TCS (data
ot shown). Single spot urine samples had signiﬁcantly lower accu-
acy when predicting exposure into a medium exposure category
2 = 25.66, p < 0.0001). Accuracy was signiﬁcantly higher among
amples collected on a week-day when compared to those collected
n a week-end day (2 = 11.28, p = 0.0008) (Tables 5a and 5b). When
ssessing the accuracy of a single spot sample to predict geomet-
ic mean urinary TCS concentrations representing high exposure,
amples collected between 09:00 and 15:59 (2 = 15.52, p = 0.0004)
ad signiﬁcantly higher accuracy (Table 5c).
iscussion and limitations
This study provided the ﬁrst Canadian data on personal care
roduct use and urinary maternal TCS concentrations through-
ut pregnancy. It indicated that pregnant women were exposed to
CS through product sources such as oral care products and hand
oaps/sanitizers; the detection of maternal urinary TCS concentra-
ions persisted throughout the duration of the pregnancy as well
s postpartum.
Our study ﬁndings showed that products containing TCS were
rimarily “oral care products” and “hand soaps/sanitizers”. Meeker
t al. (2013) reported that liquid soap and hair spray use were
ssociated with higher urinary TCS concentrations and Koch and
olleagues (2014) reported that urinary concentrations were sub-
tantially higher in urine of adults using toothpaste with TCS. Uses
f antibacterial soaps in healthcare settings and TCS-containing
oothpaste have also been shown to increase urinary TCS concen-
rations in healthcare workers (MacIsaac et al., 2014); however a
wedish study of mothers reported no obvious differences in TCS
evels between users and nonusers of products which may  contain
CS, although only 37% of the urine samples were above the detec-
ion limit (Larsson et al., 2014). Estimating a quantitative dose of Environmental Health 218 (2015) 507–513 511
TCS based on the speciﬁc product would provide additional infor-
mation with respect to primary sources of exposure to TCS and
would be an important future research direction.
The unadjusted geometric mean maternal urinary TCS con-
centration reported in this study (21.6 g/L) was higher than
several previously reported studies of pregnant women in
Canada (Arbuckle et al., 2015a; 12.64 g/L), Boston (LaRocca
et al., 2014; 13.8 g/L), the US NHANES (Woodruff et al., 2011;
17.0 g/L), Norway (Bertelsen et al., 2014; <2.3 g/L), and Denmark
(Frederiksen et al., 2014; 1.21 g/L). Our maternal TCS concentra-
tions were comparable to those of pregnant women in California
(California, 2013; 17.2 g/L), multiple US sites (Mortensen et al.,
2014; 19.0 g/L) and in Canadian women  of reproductive age
(Health Canada, 2013; 19.0 g/L) or in the case of a study in
Puerto Rico, lower (Meeker et al., 2013; 29.9 g/L). A number of
factors such as number of collections, socio-economic status and
availability of triclosan-containing products may account for these
differences. The overall intraclass correlation coefﬁcient of 0.50
indicated moderate reproducibility among urine samples collected
across pregnancy. This result was  comparable to that of recent stud-
ies (Meeker et al., 2013; Philippat et al., 2013; Bertelsen et al., 2014),
who reported adjusted intraclass coefﬁcients between 0.47 and
0.58, based on several spot samples collected over the pregnancy.
The intraclass correlation coefﬁcients of the P4 study 24-h unad-
justed serial urine samples were 0.78 for week-day samples and
0.79 for week-end day samples, both indicating high reproducibil-
ity for samples collected within a day. In a Belgian adult population
where all urine voids were collected over 6 days, the ICC for spot
samples was 0.93 (Koch et al., 2014). This result is not surprising
given the correlation between product uses and urinary TCS lev-
els and assuming that the same products are used on consecutive
days. In agreement with Bertelsen et al. (2014), our results suggest
that given the costs and participant burden of collecting serial urine
samples, a single spot urine sample can moderately represent a per-
son’s exposure over the pregnancy and can be especially relevant
for women  with high exposure.
The surrogate category analysis indicated that the predictive
ability of a single spot urine sample was  lower when identifying
individuals with moderate urinary metabolite concentrations, as
compared to high concentrations. A recent Health Canada publica-
tion (Saner, 2010) emphasized the importance of exposure in risk
assessments, as a higher exposure may  increase the chances of an
adverse health effect; however, in the speciﬁc case of endocrine
disrupting chemicals, health effects can occur at lower levels of
exposure that would not have been predicted based on exposures
at higher levels (Vandenberg et al., 2012). In this study, single spot
urine samples correctly predicted high metabolite concentrations
(GM > 78.12 g/L) more than 90% of the time, and correctly pre-
dicted low metabolite concentrations (GM < 11.77 g/L) between
86% and 96% of the time.
Univariate models controlling for speciﬁc gravity were pre-
viously reported (Arbuckle et al., 2015b). Similar results were
observed in the multivariate model of this study. SG-adjusted uri-
nary TCS concentrations were lowest between 16:00 and 23:59.
As the urinary half-life of TCS is approximately 11 h (Sandborgh-
Englund et al., 2006), the low concentrations at this time are likely a
reﬂection of a low number of TCS product uses in the early morning
hours.
In our study, women with household incomes between $80,000
and 100,000 had signiﬁcantly lower TCS exposure than women
with incomes greater than $100,000. This result agrees with a
larger study of Canadian pregnant women  which reported a posi-(Arbuckle et al., 2015a). Similarly, both studies concluded that
women with no previous pregnancies had the highest urinary GM
TCS.
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Similar to other studies (Woodruff et al., 2011; Meeker et al.,
013; Philippat et al., 2013), our sample was highly educated. It
s unknown how this may  have inﬂuenced their exposure to TCS;
owever, it does limit the generalizability of the study results to
ther socio-demographic strata. A larger sample size would have
ncreased the precision and power of the results; and may  have
esulted in ﬁnding associations between urinary TCS and age and
ducation, as previous studies have reported (Wolff et al., 2008; Ye
t al., 2008; Kim et al., 2011).
An important limitation of the study is self-selection bias occur-
ing among the participants. This may  have been reﬂected by
omen who reported using TCS-containing products providing far
ore urine samples than those who did not report using any TCS-
ontaining products.
Another limitation of the study is that approximately 25% of all
elf-reported product uses had insufﬁcient information to properly
dentify whether or not TCS was an active ingredient in the prod-
ct. It is possible that the actual number of TCS products used may
e greater than 4.41%. Although efforts were made to make the
ompletion of the “Product Use Booklets” and “Food and Activity
iaries” as user-friendly as possible, it is anticipated that miss-
ng data (and therefore under-reporting of products) are a concern.
mong the women reporting to not have been exposed to TCS, they
till had detectable levels of TCS in their urine samples, although
t was lower than those who did report exposure to TCS products.
his likely also reﬂects the under-reporting of triclosan use.
ummary and conclusions
This study set out to address the existing knowledge gaps per-
aining to urinary TCS data in Canadian pregnant women. It was
he ﬁrst of its kind to provide data on personal care product use
nd urinary maternal TCS concentrations within a day on a week-
ay and week-end and throughout pregnancy. It also provided
ritical information on the ability of a single spot urine sample col-
ected in pregnancy to accurately predict the woman’s exposure
o TCS (87%). Urinary TCS concentrations tended to be consistent
cross pregnancy, with concentrations lowest for samples collected
etween 16:00 and 23:59.
A positive association was observed between the number of TCS
roducts used and urinary TCS concentrations. However, as only
bout a quarter of the variance in TCS concentrations was  explained
y this metric, further research is needed to identify the primary
ources.
As the data reﬂect a small subset of the Canadian population, the
tudy results may  not be generalizable to other populations; how-
ver, they provide important information towards understanding
he nature of and some of the sources of exposure to TCS.
Additional studies are required to further examine the associ-
tions between speciﬁc covariates and urinary TCS concentrations
nd conﬁrm the results that were found in this study.
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